Cambridge, United States
Nabla Bio is innovating the pharmaceutical landscape by designing antibodies with atomic precision. This startup leverages cutting-edge AI and wet-lab technologies to create drugs for targets previously considered undruggable. Their approach promises to transform drug development, potentially doubling the number of viable drug targets.
In strategic partnerships with top-tier pharmaceutical companies like AstraZeneca, Bristol Myers Squibb, and Takeda, Nabla Bio is poised to deliver high-quality drug candidates that could significantly impact patient outcomes. Since its 2021 launch, the company has successfully raised $37 million from prominent investors such as Radical Ventures, Khosla Ventures, and Zetta Venture Partners.
Headquartered in the United States with its technical team in Cambridge, Massachusetts, Nabla Bio is actively expanding its pool of machine learning and synthetic biology experts, positioning itself as a leader in biotechnology innovation.
